Literature DB >> 23086683

Overexpression of NEDD9 is associated with altered expression of E-Cadherin, β-Catenin and N-Cadherin and predictive of poor prognosis in non-small cell lung cancer.

Yuan Miao1, Ai-Lin Li, Liang Wang, Chui-Feng Fan, Xiu-Peng Zhang, Hong-Tao Xu, Lian-He Yang, Yang Liu, En-Hua Wang.   

Abstract

Neural precursor cell expressed, developmentally down-regulated 9 (NEDD9) is overexpressed in multiple tumor types, where it is thought to regulate tumor cell metastasis and act as a trigger of the epithelial-mesenchymal transition (EMT). Loss of E-cadherin/β-catenin and upregulation of N-cadherin are hallmarks of the EMT. The expression and correlation of NEDD9 with E-cadherin, β-catenin and N-cadherin in lung cancer are poorly characterized. We examined NEDD9, E-cadherin, β-catenin and N-cadherin protein expression in 105 cases of non-small cell lung carcinoma (NSCLC), including 43 cases of squamous cell carcinoma and 62 cases of lung adenocarcinoma, and the corresponding normal lung tissues using immunohistochemistry. NEDD9 was overexpressed in 56.2 % (59/105) of the NSCLC samples compared to normal lung tissue. Overexpression of NEDD9 correlated with abnormal expression of E-cadherin, β-catenin and N-cadherin (P < 0.001, P = 0.008 and P = 0.027, respectively). Additionally, overexpression of NEDD9 correlated positively with lymph node metastasis in NSCLC (Chi-square test; P = 0.015). The mean overall survival of NSCLC patients overexpressing NEDD9 (39.10 ± 6.49 months) was markedly shorter than patients with normal NEDD9 expression (56.67 ± 7.44 months; Log-Rank, P = 0.001). Moreover, for patients with adenocarcinoma or squarmous cell carcinoma, the survival is also dramatically poorer upon overexpression of NEDD9. In multivariate analysis, overexpression of NEDD9 (P = 0.013) and TNM stage (P = 0.001) were significant independent prognostic factors for overall survival in NSCLC. In conclusion, overexpression of NEDD9 correlates with altered expression of EMT markers, increased lymph node metastasis and poorer survival in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23086683     DOI: 10.1007/s12253-012-9580-2

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  22 in total

1.  LKB1 modulates lung cancer differentiation and metastasis.

Authors:  Hongbin Ji; Matthew R Ramsey; D Neil Hayes; Cheng Fan; Kate McNamara; Piotr Kozlowski; Chad Torrice; Michael C Wu; Takeshi Shimamura; Samanthi A Perera; Mei-Chih Liang; Dongpo Cai; George N Naumov; Lei Bao; Cristina M Contreras; Danan Li; Liang Chen; Janakiraman Krishnamurthy; Jussi Koivunen; Lucian R Chirieac; Robert F Padera; Roderick T Bronson; Neal I Lindeman; David C Christiani; Xihong Lin; Geoffrey I Shapiro; Pasi A Jänne; Bruce E Johnson; Matthew Meyerson; David J Kwiatkowski; Diego H Castrillon; Nabeel Bardeesy; Norman E Sharpless; Kwok-Kin Wong
Journal:  Nature       Date:  2007-08-05       Impact factor: 49.962

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression.

Authors:  Y Li; J H Bavarva; Z Wang; J Guo; C Qian; S N Thibodeau; E A Golemis; W Liu
Journal:  Oncogene       Date:  2011-02-14       Impact factor: 9.867

4.  Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation.

Authors:  Gabriela I Rozenberg; Kimberly B Monahan; Chad Torrice; James E Bear; Norman E Sharpless
Journal:  Melanoma Res       Date:  2010-10       Impact factor: 3.599

Review 5.  Pathology of lung cancer.

Authors:  William D Travis
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

6.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

Review 7.  A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9.

Authors:  Geraldine M O'Neill; Sachiko Seo; Ilya G Serebriiskii; Stuart R Lessin; Erica A Golemis
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

8.  Dissection of HEF1-dependent functions in motility and transcriptional regulation.

Authors:  Sarah J Fashena; Margret B Einarson; Geraldine M O'Neill; Christos Patriotis; Erica A Golemis
Journal:  J Cell Sci       Date:  2002-01-01       Impact factor: 5.285

9.  NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer.

Authors:  Chenfei Kong; Changqing Wang; Liping Wang; Musong Ma; Chunbo Niu; Xiaoqian Sun; Juan Du; Zhixiong Dong; Shan Zhu; Jun Lu; Baiqu Huang
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

10.  Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.

Authors:  Ludmila Prudkin; Diane D Liu; Natalie C Ozburn; Menghong Sun; Carmen Behrens; Ximing Tang; Kathlynn C Brown; B Nebiyou Bekele; Cesar Moran; Ignacio I Wistuba
Journal:  Mod Pathol       Date:  2009-03-06       Impact factor: 7.842

View more
  17 in total

1.  Overexpression of N-cadherin and β-catenin correlates with poor prognosis in patients with nasopharyngeal carcinoma.

Authors:  Hong Sun; Mingyu Liu; Xuewen Wu; Chunguang Yang; Yanni Zhang; Zhenhang Xu; Kelei Gao; Fengjun Wang
Journal:  Oncol Lett       Date:  2017-01-25       Impact factor: 2.967

2.  Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis.

Authors:  Jiajia Jin; Ping Zhan; Masaru Katoh; Susumu S Kobayashi; Kevin Phan; Hong Qian; Huijuan Li; Xiaoxia Wang; Xihua Wang; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

Review 3.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

4.  NEDD9 Restrains dsDNA Damage Response during Non-Small Cell Lung Cancer (NSCLC) Progression.

Authors:  Mariya Tikhomirova; Iuliia Topchu; Aleksandra Mazitova; Vitaly Barmin; Ekaterina Ratner; Alexey Sabirov; Zinaida Abramova; Alexander Y Deneka
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

5.  Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells.

Authors:  Jin Dai; Peter G Van Wie; Leonard Yenwong Fai; Donghern Kim; Lei Wang; Pratheeshkumar Poyil; Jia Luo; Zhuo Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2016-09-20       Impact factor: 4.219

Review 6.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

Review 7.  CAS proteins in health and disease: an update.

Authors:  Anna S Nikonova; Anna V Gaponova; Alexander E Kudinov; Erica A Golemis
Journal:  IUBMB Life       Date:  2014-06-24       Impact factor: 3.885

8.  Overexpression of CASS4 promotes invasion in non-small cell lung cancer by activating the AKT signaling pathway and inhibiting E-cadherin expression.

Authors:  Ailin Li; Weiwei Zhang; Huifang Xia; Yuan Miao; Haijing Zhou; Xiupeng Zhang; Qianze Dong; Qingchang Li; Xueshan Qiu; Enhua Wang
Journal:  Tumour Biol       Date:  2016-09-27

9.  Nedd9 Restrains Autophagy to Limit Growth of Early Stage Non-Small Cell Lung Cancer.

Authors:  Alexander Y Deneka; Meghan C Kopp; Anna S Nikonova; Anna V Gaponova; Anna A Kiseleva; Harvey H Hensley; Douglas B Flieder; Ilya G Serebriiskii; Erica A Golemis
Journal:  Cancer Res       Date:  2021-05-18       Impact factor: 12.701

10.  Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis.

Authors:  Zhongquan Zhao; Xiaoming Cheng; Yubo Wang; Rui Han; Li Li; Tong Xiang; Luhang He; Haixia Long; Bo Zhu; Yong He
Journal:  PLoS One       Date:  2014-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.